Opendata, web and dolomites

ViroPedTher SIGNED

Oncolytic viruses for the treatment of pediatric brain tumors: An integrated clinical and lab approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ViroPedTher project word cloud

Explore the words cloud of the ViroPedTher project. It provides you a very rough idea of what is the project "ViroPedTher" about.

therapeutic    quality    adenovirus    tumor    complete    improvement    replication    profound    virus    regression    previously    immunosuppression    oncolysis    understand    hypothesized    patients    dipgs    diffuse    propelled    opened    context    oncolytic    activate    experimental    delayed    life    capacity    preliminary    brain    2401    turn    ed    rgd    dipg    trials    combinatorial    pontine    team    newly    viral    competent    enhancement    clinical    integrate    treatment    dnx    intrinsic    diagnosed    vast    toxicities    overreaching    translated    ligands    delta    trial    risk    lymphocytes    infiltrating    worked    scenario    2017    competence    recruit    majority    vertical    24    immune    therapy    inflammatory    leverage    models    intratumoral    inherent    microenvironment    anti    oncology    revealed    gliomas    followed    lethal    lab    injection    prognosis    pediatric    initial    adenoviruses    instigated    subset    ing    innovative    first    elicit    tumors    ultimately   

Project "ViroPedTher" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE NAVARRA 

Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL
city: PAMPLONA
postcode: 31080
website: www.unav.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-COG
 Funding Scheme ERC-COG
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) coordinator 2˙000˙000.00

Map

 Project objective

The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses with the capacity to elicit a therapeutic immune response in those tumors. Our research will use novel and relevant models to accomplish the experimental aims. We have previously worked with Delta-24-RGD (DNX-2401) a replication-competent adenovirus that has been translated to the clinical scenario. In 2017, the first clinical trial phase I with DNX-2401 for newly diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG; a lethal pediatric brain tumor) opened propelled by my team. Preliminary results from the first trials revealed that the intratumoral injection of the virus instigated an initial phase of oncolysis followed by a delayed inflammatory response that ultimately resulted in complete regression in a subset of the patients without associated toxicities. I hypothesized that enhancement of the immune component of the DNX-2401-based therapy will result in the complete regression of the vast majority of pediatric brain tumors. In our specific approach, we propose to understand the immune microenvironment of DIPGs and the response to viral therapy in the context of the trial. Moreover, that knowledge will leverage the design of Delta-24-based adenoviruses to recruit lymphocytes to the tumor with the competence of different type of ligands to activate the tumor infiltrating lymphocytes. I expect that this combinatorial innovative treatment will efficiently challenge the profound and inherent tumor immunosuppression and, in turn, will elicit a robust anti-tumor immune response resulting in the significant improvement of the prognosis and quality of life of patients with pediatric brain tumors. This project has the potential to produce a vertical advance in the field of pediatric oncology.

 Publications

year authors and title journal last update
List of publications.
2019 Naiara Martínez-Vélez, Marc Garcia-Moure, Miguel Marigil, Marisol González-Huarriz, Montse Puigdelloses, Jaime Gallego Pérez-Larraya, Marta Zalacaín, Lucía Marrodán, Maider Varela-Guruceaga, Virginia Laspidea, Jose Javier Aristu, Luis Isaac Ramos, Sonia Tejada-Solís, Ricardo Díez-Valle, Chris Jones, Alan Mackay, Jose A. Martínez-Climent, Maria Jose García-Barchino, Eric Raabe, Michelle
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-10043-0
Nature Communications 10/1 2020-02-05
2019 Ignacio Iñigo-Marco, Marta M. Alonso
Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression
published pages: 5086-5088, ISSN: 0021-9738, DOI: 10.1172/jci133115
Journal of Clinical Investigation 129/12 2020-02-05
2019 Donatas Stakišaitis, Milda Juknevičienė, Eligija Damanskienė, Angelija Valančiūtė, Ingrida Balnytė, Marta Maria Alonso
The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo
published pages: 1210, ISSN: 2072-6694, DOI: 10.3390/cancers11081210
Cancers 11/8 2020-02-05
2019 Naiara Martinez-Velez, Miguel Marigil, Marc García-Moure, Marisol Gonzalez-Huarriz, Jose Javier Aristu, Luis-Isaac Ramos-García, Sonia Tejada, Ricardo Díez-Valle, Ana Patiño-García, Oren J. Becher, Candelaria Gomez-Manzano, Juan Fueyo, Marta M. Alonso
Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models
published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-019-0714-6
Acta Neuropathologica Communications 7/1 2020-02-05
2019 Marc Garcia-Moure, Naiara Martinez-Velez, Marisol Gonzalez-Huarriz, Lucía Marrodán, Manel Cascallo, Ramón Alemany, Ana Patiño-García, Marta M. Alonso
The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-019-51014-1
Scientific Reports 9/1 2020-02-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIROPEDTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIROPEDTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More